ICU Medical FY Conference Summary Company Overview - **Company**: ICU Medical (NasdaqGS:ICUI) - **Industry**: Medical Technology Key Points Market Environment - The U.S. market for surgeries and hospital admissions appears healthy, with volumes increasing but not at a substantial rate year over year [6][8] - No significant decrease in hospital census; flu season is starting later than usual, but this does not heavily impact business [8][12] Capital Spending - Less than 10% of ICU Medical's $2 billion revenue comes from capital sales, primarily infusion pumps [12] - Capital purchases are necessary for modern devices, and U.S. customers are allocating capital as needed [12] Consumables Business Growth - The consumables segment has shown strong growth, compounding at 5-6% annually for over five years, driven by strong volumes and market share gains due to industry events like IV fluid shortages [14][15] - ICU Medical retains business gained from IV Solutions shortages, with limited competition in the market [15] Infusion Pumps - The infusion pump market is experiencing increased activity due to regulatory challenges faced by competitors, leading to more requests for proposals (RFPs) [21][22] - ICU Medical has a 20% share of the U.S. LVP (Large Volume Pump) install base, with opportunities for market share gains and technology refreshes expected to begin in late 2026 [32][34] Software and Technology Integration - ICU Medical is focusing on integrating its devices with a single software solution (LifeShield), enhancing ease of use and operational efficiency for hospitals [45][56] - The company believes that the new software will have long-term P&L implications by justifying higher pricing for software services [53][56] Financial Outlook - ICU Medical has seen gross margins improve from a low of 35% to around 41%, with a target of reaching 45% in the future [72][75] - The company is managing tariff impacts, with a current burden of $25 million, and is exploring operational adjustments to mitigate costs [70][72] Regulatory and Compliance - ICU Medical is in regular dialogue with the FDA regarding warning letters and product approvals, with most remediation work completed [81][83] - The company anticipates that the lifting of warning letters will be contingent on the approval of new products [81] Cash Management and Future Strategy - ICU Medical is focused on deleveraging to a target of two times debt, after which it may consider stock buybacks or other capital allocation strategies [84][96] - The company emphasizes the importance of innovation and product development in both pumps and consumables to drive future growth [88][90] Conclusion - ICU Medical is positioned in a healthy market environment with strong growth in consumables and opportunities in infusion pumps. The integration of software solutions and a focus on improving margins are key strategies moving forward. The company is also managing regulatory challenges and planning for future capital allocation once debt levels are optimized.

Repligen (NasdaqGS:RGEN) FY Conference December 03, 2025 01:20 PM ET Company ParticipantsStephen Shah - Head of Investor RelationsJason Garland - CFOConference Call ParticipantsDaniel Markowitz - AnalystDaniel MarkowitzAre we live? Great. Awesome. Thank you, everyone, for joining. For those of you who don't know me, I'm Daniel Markowitz. I cover the life science, tools, and diagnostics and med tech space here at Evercore ISI. Today we're joined by Repligen. We have with us CFO Jason Garland and, from Invest ...

National Vision Conference Call Summary Company Overview - **Company**: National Vision (NasdaqGS:EYE) - **Industry**: Optical Retail Key Insights and Arguments 1. **Leadership Changes**: Alex Wilkes joined National Vision in 2024 and became CEO in August, bringing extensive experience from EssilorLuxottica and The Cooper Companies [2][3][4] 2. **Consumer Insights**: A retrospective analysis revealed that National Vision's customer base is wealthier than previously thought, leading to changes in product assortment and pricing strategy [4][5] 3. **Business Model Transformation**: The company is undergoing a significant transformation of its commercial model, focusing on better meeting the needs of its existing customer base and optimizing its product offerings [8][9][10] 4. **Cost Optimization**: In 2025, National Vision identified $12 million in cost reductions and plans to eliminate an additional $20 million in costs by 2027, focusing on indirect spending and procurement [11][12][54] 5. **Market Position**: National Vision holds approximately 3% market share in a $70 billion U.S. optical market, with significant opportunities to gain share from independent retailers [15][16] 6. **Growth Vectors**: The company identified four growth vectors: targeting underdeveloped customer segments, enhancing product offerings, improving customer experience, and expanding physical store count [23][24][26] 7. **Product Development**: National Vision plans to shift its product mix from basic plastic lenses to higher-end options, which could significantly impact revenue [25][41] 8. **E-commerce and Technology**: The company is migrating its e-commerce platform to Adobe Experience Platform to enhance customer experience and streamline operations [26][58] 9. **Store Growth Strategy**: National Vision is reducing new store openings in 2026 and 2027 to focus on reinvesting in existing stores and improving product offerings [27][58] 10. **Remote Care Services**: The company is expanding its remote care capabilities, with over 730 locations enabled for remote services, aiming to enhance patient care and operational efficiency [46][49] Additional Important Points 1. **Consumer Behavior**: The cash-pay consumer segment is showing signs of recovery, with positive purchasing trends noted in Q3 [21][22] 2. **Managed Care Focus**: National Vision aims to increase its managed care customer base from 40% to 50% by improving product offerings and customer service [35][36] 3. **Profitability Goals**: The company targets annual operating margin expansion of 50 to 150 basis points over the next five years, driven by cost optimization and better serving profitable customer segments [54][55] 4. **Doctor Recruitment and Retention**: National Vision has strengthened its value proposition for doctors, focusing on recruitment and retention strategies to maintain a strong workforce [52][53] 5. **Long-term Projections**: The company is confident in achieving high single-digit revenue growth and mid-single-digit comparable store sales growth, supported by its strategic initiatives [43][45] This summary encapsulates the key points discussed during the National Vision conference call, highlighting the company's strategic direction, market opportunities, and operational improvements.

Core Viewpoint - C.H. Robinson Worldwide (CHRW) reported mixed third-quarter 2025 results, with earnings exceeding estimates but revenues falling short, leading to questions about the sustainability of its recent positive stock performance [3][4][16]. Financial Performance - Quarterly earnings per share were $1.40, surpassing the Zacks Consensus Estimate of $1.29, reflecting a year-over-year improvement of 9.3% [4]. - Total revenues amounted to $4.14 billion, missing the Zacks Consensus Estimate of $4.29 billion and declining 10.9% year over year due to the divestiture of the Europe Surface Transportation business and lower pricing and volume in ocean and truckload services [4]. - Adjusted gross profits decreased by 4% year over year to $706.1 million, impacted by lower transaction volume in ocean services and the divestiture, although partially offset by higher profits in less than truckload (LTL) and customs services [6]. Segment Performance - North American Surface Transportation revenues were $2.96 billion, up 1.1% year over year, driven by higher volumes in truckload and LTL services, despite lower pricing in truckload services [8]. - Global Forwarding revenues fell 31.1% year over year to $786.34 million, attributed to lower pricing and volume in ocean services [9]. - Adjusted gross profits for the Transportation unit were $670.85 million, down 4.5% from the prior year, with LTL, Air, Customs, and Other logistics services showing growth, while Truckload and Ocean services experienced declines [10]. Balance Sheet and Cash Flow - Cash and cash equivalents at the end of the third quarter were $136.83 million, down from $155.99 million in the previous quarter, while long-term debt increased to $1.18 billion from $922.31 million [11]. - Cash generated from operations was $275.4 million, significantly up from $108.1 million in the same quarter last year, driven by increased net income and reduced cash used in working capital [12]. Shareholder Returns and Capital Expenditures - The company returned $189.6 million to shareholders, including $74.7 million in dividends and $114.9 million in share repurchases, with capital expenditures totaling $18.6 million for the quarter [13]. - For the full year 2025, capital expenditures are expected to be between $65 million and $75 million [13]. Market Sentiment and Outlook - There has been a downward trend in earnings estimates, with a consensus estimate shift of -5.37% [14]. - C.H. Robinson holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [16].

Core Viewpoint - Walmart Inc. reported strong quarterly earnings, exceeding profit expectations and raising its outlook for the upcoming year, yet its stock price fell [1][2]. Financial Performance - Walmart's third-quarter adjusted earnings were 62 cents per share, surpassing the Street's estimate of 60 cents [2]. - The company raised its adjusted EPS forecast for 2026 to a range of $2.58–$2.63, up from the previous range of $2.52–$2.62 [2]. Analyst Ratings and Forecasts - Analysts maintain a positive outlook on Walmart, citing strong momentum in value, convenience, and higher-margin services like advertising [3]. - Bank of America Securities analyst Robert F. Ohmes maintained a Buy rating with a price target of $125, emphasizing Walmart's value proposition and digital convenience [4]. - Goldman Sachs analyst Kate McShane reiterated a Buy rating and increased her forecast from $114 to $121, highlighting Walmart's potential for solid earnings growth [5]. - JPMorgan analyst Christopher Horvers raised his forecast from $128 to $129, noting that results alleviated concerns about consumer health [6]. - DA Davidson's Michael Baker raised his forecast from $117 to $130, while increasing EPS estimates for 2025 and 2026 [7]. - BTIG analyst Robert Drbul lifted his forecast from $120 to $125, expecting operating income to rise faster than sales [8]. - Guggenheim's John Heinbockel raised his forecast from $115 to $120, noting Walmart's strong performance compared to the S&P 500 [9]. - KeyBanc Capital Markets analyst Bradley B. Thomas increased his forecast from $110 to $120, citing growth initiatives and supply chain automation [10]. - RBC Capital Markets analyst Steven Shemesh maintained an Outperform rating with a $116 forecast, highlighting the benefits of Walmart's third-party marketplace [11]. - Telsey Advisory Group's Joseph Feldman raised his forecast from $118 to $130, encouraged by Walmart's expansion beyond core retail [12].

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $533 million, representing a 5% organic growth but an 8% decline reported year over year due to the deconsolidation of IV solutions [5][6] - Adjusted EBITDA increased by 12% to $106 million compared to $95 million last year, while adjusted diluted EPS rose by 28% to $2.03 from $1.59 [18][21] - Gross margin for Q3 was 41%, slightly better than expectations, with improvements attributed to the deconsolidation of IV solutions and a one-time benefit from settling a liability [14][15] Business Line Data and Key Metrics Changes - The consumables business grew 8% reported and 7% organic, driven by new customer implementations and growth in niche markets [7][9] - The IV systems business experienced a 9% reported growth and 8% organic growth, with strong contributions from LVP pumps and dedicated sets [9][10] - The vital care segment saw a significant decline of 52% reported and 4% organic due to the deconsolidation of IV solutions [13] Market Data and Key Metrics Changes - The demand and utilization environment remained attractive across almost all geographies, although growth rates were not as high as the previous year [6] - The capital environment is stable, with customers proceeding with necessary investments [6] Company Strategy and Development Direction - The company aims to build a comprehensive infusion therapy company, focusing on innovation and expanding its product portfolio [26][27] - The strategy includes enhancing patient safety and workflow efficiencies through new product developments and maintaining a competitive edge in the market [12][27] - The company is also focused on optimizing its balance sheet and reducing leverage over time, with a target of around two times levered net debt to EBITDA [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit growth for the consumables and IV systems businesses for the remainder of the year [7][10] - The company is increasing its full-year EBITDA guidance from $380 million-$390 million to $395 million-$405 million, and adjusted EPS guidance from $6.85-$7.15 to $7.35-$7.65 [21][22] - Management acknowledged challenges from tariffs and the absence of one-time benefits in future quarters but remains optimistic about overall performance [22][23] Other Important Information - The company has made significant progress in reducing debt, with $273 million repaid year to date [20] - Free cash flow for the quarter was $28 million, with expectations for improved cash flow generation as restructuring costs decrease [19][56] Q&A Session Summary Question: Sources of strength in consumables growth - Management identified several drivers including market share gains, successful customer implementations, and growth in niche markets like oncology and dialysis [33][34] Question: Expectations for consumables growth in Q4 - Management indicated that while they expect growth, it may not match the sequential lift seen from Q2 to Q3, maintaining a cautious outlook [37] Question: Traction of Duo and Solo infusion systems - Management confirmed that they are taking orders for Solo and noted ongoing discussions in the pump market, with installations still in early stages [38] Question: 2026 tariff exposure outlook - Management reiterated that they do not want to annualize the tariff impact and are actively working on mitigation strategies [41][42] Question: Future gross margin targets and earnings growth - Management discussed the potential for earnings growth through technology value, product mix, and financial leverage, while acknowledging the need to close the gap to their gross margin targets [44][45] Question: Updates on FDA warning letters - Management confirmed ongoing dialogue with the FDA and emphasized their focus on obtaining new product approvals [61][62] Question: Portfolio management within the vital care segment - Management stated they are exploring all available avenues for portfolio optimization but emphasized the importance of not engaging in value-destructive actions [64][66]

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 reached a record $260.5 million, up 9.3% year over year, driven by strong organic growth in both single-family residential and multi-family commercial businesses [4][12] - Adjusted EBITDA for Q3 2025 was $79.1 million, representing an adjusted EBITDA margin of 30.4%, compared to $81.4 million and a 34.2% margin in the prior year [12][13] - Gross profit was $111.3 million, with a gross margin of 42.7%, down from a gross profit of $109.2 million and a 45.8% margin in the prior year [12][13] Business Line Data and Key Metrics Changes - Single-family residential revenue grew 3.4% year over year to a record $113.5 million, benefiting from pricing initiatives and market share gains [4][9] - Multi-family and commercial business revenue increased 14.3% year over year to a record $147 million, reflecting market share gains and project execution [5][8] - The backlog reached a record $1.3 billion, up over 20% year over year, indicating strong demand and project pipeline [5][8] Market Data and Key Metrics Changes - The company reported a healthy book-to-bill ratio of 1.3x for Q3, maintaining a ratio above 1.1x for 19 consecutive quarters [8] - The composition of the backlog has shifted towards high-end, large-sized projects, which are less sensitive to interest rate fluctuations [8][9] Company Strategy and Development Direction - The company is focused on geographic expansion and product diversification, with plans for a new fully automated facility in Florida to enhance manufacturing capabilities [10][11] - The board authorized an expansion of the share repurchase program to $150 million, reflecting confidence in the business and commitment to balanced capital allocation [6][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver exceptional shareholder value, supported by a strong balance sheet and record backlog [6][20] - The updated full-year 2025 financial guidance anticipates revenues in the range of $970 million to $990 million, reflecting approximately 10% growth at the midpoint [18][19] Other Important Information - The company generated operating cash flow of $40 million in Q3, driven by strong profitability and efficient working capital management [15][16] - Capital expenditures for the quarter were $18.8 million, with expectations for moderation through year-end [15][16] Q&A Session Summary Question: Context around 2026 double-digit growth visibility - Management highlighted a record backlog providing visibility, especially for larger projects, and growth driven by geographical expansion and vinyl product ramp-up [24] Question: Trends in aluminum costs and FX impacts - Management noted a significant increase in aluminum prices and U.S. aluminum premiums, with expectations for normalization as demand subsides [25][26] Question: Update on the vinyl business performance - The company expects vinyl business to grow significantly in 2026, with a complete product line and new dealer partnerships [28] Question: Pricing and tariff costs for 2026 - Management indicated that pricing adjustments have been implemented, and gross margins are expected to maintain a low to mid-40% range [33][34] Question: Capacity and CapEx for the new U.S. facility - The projected total cost for the new facility is around $350 million to $400 million, with a multi-year investment timeline [35][39] Question: Impact of slower invoicing in light commercial construction - Management estimated a $20 million reduction in revenue guidance, with half expected to shift to 2026 [43] Question: Market conditions for high-end space and backlog growth - The company is expanding geographically and capturing market share, particularly in Florida and other states [55]

Financial Data and Key Metrics Changes - Total global net sales reached $203.4 million, a 6% increase over the prior year, driven by strong performance in US spine and orthopedic segments [13] - Pro forma non-GAAP adjusted gross margin reached 72.1%, up 80 basis points from Q3 2024, driven by the discontinuation of M6 and productivity improvements [15] - Pro forma non-GAAP adjusted EBITDA was $24.6 million, or 12.1% of net sales, with year-over-year margin expansion of 230 basis points [16] - Generated positive free cash flow of $2.5 million, ending the quarter with $65.9 million in total cash [16] Business Line Data and Key Metrics Changes - US spine fixation segment net sales increased 8%, with procedural volume up 10% [5] - US orthopedics grew 19%, marking the fifth consecutive quarter of double-digit growth [9] - Bone Growth Therapies (BGT) achieved $61.2 million in net sales, reflecting 6% growth [15] Market Data and Key Metrics Changes - International spine fixation net sales grew by 86% year-over-year [14] - The US pedicle screw market, valued at approximately $2 billion in 2025, is projected to grow at a steady 4%-5% compound annual growth rate through 2030 [8] Company Strategy and Development Direction - Focus on sharpening commercial execution, improving gross margin, and maintaining disciplined capital allocation [10] - Advancing a data-driven deformity strategy with access to pre-operative planning and patient-specific roads beginning in Q1 of next year [9] - Aiming for a full launch of the Virada Spinal Fixation System in the second half of next year [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver strong operational and financial performance through the remainder of 2025 [19] - The company is well-positioned for its next phase of profitable growth with a streamlined product portfolio and optimized commercial channel [10] - Anticipated continued momentum in spine, BGT, and orthopedics businesses supported by a robust innovation pipeline [18] Other Important Information - The company is raising the bottom end of its full-year 2025 pro forma non-GAAP adjusted EBITDA guidance range to $84 million, with an updated range of $84 million-$86 million [17] - The guidance excludes revenue from the discontinued M6 product lines and implies fourth-quarter pro forma net sales will be approximately $219 million [17] Q&A Session Summary Question: Near-term revenue guidance and Q4 expectations - Management indicated that guidance was set appropriately, considering a strong Q4 last year and comparability issues [23] Question: Long-term financial targets for 2027 - Management suggested that growth will be more weighted towards 2027, driven by the full launch of Virada and continued acceleration of TrueLok Elevate [25] Question: Key drivers of strong results in US spine - Management identified three key points: distributor transitions, innovation pipeline, and the success of the 7D technology [32] Question: Q4 free cash flow expectations - Management expects to be free cash flow positive for the second half of 2025 but does not anticipate exceeding last year's Q4 figure [34] Question: Distributor transitions and increases - Management explained that the transition involves both consolidation and expansion of distributors to enhance market presence [37] Question: Clinical validation of TrueLok Elevate - Management expressed confidence in clinical validation efforts and the potential for more studies and publications in the future [40]

Financial Data and Key Metrics Changes - Net sales for Q3 2025 were $1.56 billion, reflecting a 5% decline from $1.65 billion in the previous year due to modest declines in overall volumes and pricing [20][34] - Adjusted EBITDA decreased by 15% to $140 million, with the adjusted EBITDA margin falling to 9% from 10% a year ago [34] - Operating cash flow was $399 million, maintaining a robust cash position of over $1 billion, providing flexibility for strategic objectives [35][43] Business Line Data and Key Metrics Changes - Retail segment sales were $594 million, a 7% decline driven by softer repair and remodel demand and strategic exit from lower margin product lines [34] - ProWood volumes declined by 5%, while Deckorators achieved 5% unit growth and 8% net sales growth, including a 31% increase in SureStone decking [36] - Packaging sales were $395 million, down 2%, with a 3% organic unit decline offset by 1% growth from recent acquisitions [38] - Construction sales were $496 million, down 7%, primarily due to volume and pricing pressure in site-built units [39] Market Data and Key Metrics Changes - The company is experiencing cyclically soft demand, ongoing trade uncertainty, and competitive pricing pressures, creating a difficult operating environment [20][21] - The packaging segment is stabilizing, providing cautious optimism for 2026, while the construction market remains competitive with builders managing home inventories [29][30] Company Strategy and Development Direction - The company is focused on above-market growth with an emphasis on returns, introducing value-added products to improve margins and addressing underperforming operations through restructuring and divestitures [21][22] - A $1 billion capital expenditure program is in place, with $200 million earmarked for automation to improve throughput and lower costs [22] - M&A remains a key growth strategy, with three bolt-on acquisitions completed this year, and the company is actively exploring further transactions [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism heading into 2026, noting that while market headwinds persist, some business units are stabilizing [21][24] - The company aims for a 12.5% EBITDA margin and 7-10% unit sales growth, with a focus on driving ROIC in excess of 15% [32] - Management highlighted the importance of strategic investments and cost discipline to navigate the current environment and capitalize on future opportunities [30][31] Other Important Information - The company returned significant capital to shareholders, repurchasing nearly 6% of total outstanding shares through October [35][44] - A quarterly dividend of $0.35 per share was approved, representing a 6% increase from the previous year [44] Q&A Session Summary Question: Update on Deckorators and SureStone retail rollout - Management confirmed they are on pace for the 2026 selling season, with good sell-through and positive results despite a challenging market [48][49] Question: Impact of lumber prices on profitability - Management acknowledged that rising lumber prices could pressure profitability but emphasized their balanced pricing strategies to mitigate risks [53][54] Question: M&A opportunities versus share repurchases - The company is currently allocating more free cash flow towards share buybacks while remaining patient for meaningful M&A transactions [66][68] Question: Trends in site-built construction - Management noted that the site-built segment is facing the most significant headwinds, with unclear projections for 2026 due to consumer confidence and affordability challenges [62][63] Question: Strength of factory-built business - Management remains optimistic about the factory-built business, believing it has significant growth potential despite current market challenges [75][76] Question: Packaging business stabilization - Management feels they have found the bottom in the packaging segment and are optimistic about future growth driven by strategic sales efforts and automation investments [97][98]

Financial Data and Key Metrics Changes - MGM Resorts reported a consolidated net revenue growth this quarter, despite challenges in Las Vegas, indicating the benefits of geographic and channel diversity [5][6] - The Las Vegas segment reported $601 million in EBITDA, down $130 million year over year, attributed to decreased business interruption proceeds and operational impacts [12][13] - Net revenue in Las Vegas declined by 7%, while expenses were managed down accordingly, including a 7% decrease in full-time employees [14] Business Line Data and Key Metrics Changes - Regional operations achieved record total revenue and EBITDA, with Borgata posting all-time high table games drop and slot win [9][15] - MGM China achieved record Q3 EBITDA despite a $12 million impact from a typhoon, ending the quarter with a market share of 15.5% [15] - MGM Digital reported a revenue growth of 23% during the quarter, although segment EBITDA was a loss of $23 million due to increased investment in Brazil [16] Market Data and Key Metrics Changes - Las Vegas is expected to receive over 40 million visitors in 2025, with signs of stabilization in the luxury market segment [7][8] - In Macau, visitation increased by 11% during the Golden Week holiday period, with total win up 20% [15] - The BetMGM North American venture reported outstanding results and is expected to begin distributing cash back to MGM Resorts [15][20] Company Strategy and Development Direction - The company remains focused on premium, market-leading integrated resort operations and optimizing its portfolio for value opportunities [5][4] - MGM is committed to diversifying its business, with significant investments in Japan and digital channels, aiming for a high teens return upon opening [11][12] - The company is also exploring share buybacks as a means to enhance shareholder value, given the current undervaluation of its stock [18][50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the fourth quarter and 2026, citing strong group demand and improvements in room rates [14][23] - The company acknowledged challenges in the Las Vegas market but emphasized proactive measures to enhance customer experience and value [6][42] - Management highlighted the importance of maintaining high standards in the gaming industry and the need for continued investment in customer understanding [21][62] Other Important Information - The company announced the sale of Northfield Park for $546 million, reflecting a significant premium to MGM's current share price [5][18] - A $300 million yen-denominated credit facility was entered to support funding commitments for MGM Osaka [12] - The retirement of COO Corey Sanders was acknowledged, marking a significant transition for the company [21][22] Q&A Session Summary Question: Decision to exit New York - Management explained that the decision was influenced by high tax hurdles and competitive pressures, leading to a reassessment of capital allocation [24][25] Question: Return hurdles for investment - Current return thresholds are high due to the share price, with a focus on projects like Japan that have favorable supply-demand dynamics [26] Question: Digital growth and investment balance - Digital investments are currently cash generative, with a focus on growing existing businesses rather than pursuing inorganic growth [31] Question: Las Vegas stabilization outlook - Management indicated sequential improvement in Las Vegas, with expectations for better performance in Q4 driven by group demand [33] Question: Strategy in Macau amidst competition - MGM China focuses on quality products and customer understanding to maintain market share, with ongoing CapEx projects to enhance offerings [36][38] Question: Capital projects in Las Vegas - Management confirmed that the disruption from renovations is expected to ease, leading to improved ADR and occupancy over time [78] Question: Outlook for 2026 group events - The company anticipates a strong convention mix in the first half of 2026, which will support room occupancy and rate increases [70]